Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/7/2025

Follow-Up Plan for Dermatological Conditions

Timing of Follow-Up Visits

  • The British Journal of Dermatology recommends that follow-up visits should be scheduled weekly to biweekly until disease control is achieved, then monthly for the next 3 months, followed by every 2 months to three times a year until treatment is stopped 1
  • The frequency of follow-up should be adapted to the patient's clinical condition, disease severity and evolution, treatments used, and local health practices 1
  • For patients with generalized disease, follow-up should be more frequent initially (weekly to biweekly) until the condition is controlled 1
  • After disease control is achieved, monthly visits for 3 months are recommended, then extending to every 2 months to three times a year 1
  • The monitoring frequency should be adjusted based on the disease course and treatment response 1

Focus of Next Visit

  • Clinical examination should focus on skin disease activity, possible treatment-related side effects and comorbidities, and the degree of skin atrophy, purpura, and skin infections 1
  • Laboratory monitoring should include blood pressure monitoring, analysis of white blood cells, liver and kidney tests, glycemic value monitoring, and immune serological analyses 1
  • Treatment assessment should include evaluation of medication efficacy, safety, and tolerance 1
  • Assessment of patient compliance with prescribed therapy should be considered 2
  • Consideration of treatment adjustments based on clinical response should be taken into account 2

Special Considerations

  • If the patient is on systemic corticosteroids for more than 3 months, monitor for osteoporosis and consider vitamin D and calcium supplementation 1
  • For patients at risk, consider bisphosphonate treatment to prevent osteoporosis 1
  • If treatment fails, consider non-compliance, incorrect diagnosis, development of contact allergy to medication, or superimposed conditions 4
  • Consider osteodensitometry and ocular examination if indicated according to the treatment regimen and the patient's age and condition 1

Treatment Discontinuation Planning

  • The optimal duration of treatment has not been defined but is generally 4-12 months according to disease severity 1
  • Discontinuation of treatment should be considered in patients who are free of symptoms for at least 1-6 months under minimal therapy 1
  • Prior to cessation of treatment, DIF studies and/or ELISA for BP180 should be performed to assess risk of relapse 1